Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Hold” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned a consensus recommendation of “Hold” from the ten analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $24.50.

A number of research firms have issued reports on XNCR. Barclays increased their target price on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. raised their price target on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Zacks Research downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of XNCR. Tower Research Capital LLC TRC raised its holdings in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Xencor during the 2nd quarter valued at $79,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xencor during the 4th quarter valued at $81,000. iSAM Funds UK Ltd bought a new position in shares of Xencor during the 2nd quarter valued at $122,000. Finally, Prelude Capital Management LLC bought a new position in shares of Xencor during the 3rd quarter valued at $139,000.

Xencor Stock Up 4.8%

XNCR stock opened at $12.78 on Thursday. Xencor has a 12-month low of $6.92 and a 12-month high of $18.69. The company has a market cap of $947.51 million, a price-to-earnings ratio of -5.58 and a beta of 0.92. The company has a 50 day moving average of $12.10 and a two-hundred day moving average of $12.98.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter in the previous year, the company earned ($0.66) EPS. The firm’s quarterly revenue was down 86.2% compared to the same quarter last year. On average, research analysts anticipate that Xencor will post -3.84 EPS for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.